DAX24.217 +1,0%ESt505.379 +0,8%Top 10 Crypto15,90 -2,0%Dow44.633 -0,5%Nas21.098 -0,4%Bitcoin101.406 -0,2%Euro1,1552 -0,3%Öl72,81 +3,4%Gold3.325 +0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Novo Nordisk A3EU6F NVIDIA 918422 Rheinmetall 703000 Heidelberger Druckmaschinen 731400 RENK RENK73 Lufthansa 823212 Volkswagen (VW) vz. 766403 Tesla A1CX3T PayPal A14R7U Deutsche Bank 514000 Mercedes-Benz Group (ex Daimler) 710000 BASF BASF11 DroneShield A2DMAA Amazon 906866 HENSOLDT HAG000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt deutlich im Plus -- Wall Street beendet Handel tiefer -- PayPal mit starkem Ergebnis -- D-Wave, Novo Nordisk, Uniper, UnitedHealth, HeidelDruck, TeamViewer, Hypoport, Tilray im Fokus
Top News
Erholungsversuch gelungen: DAX legt nach schwachem Wochenstart zu - "Unsicherheit um Handelskonflikt beseitigt" Erholungsversuch gelungen: DAX legt nach schwachem Wochenstart zu - "Unsicherheit um Handelskonflikt beseitigt"
Heidelberger Druckmaschinen-Aktie +35 Prozent: Erster Auftrag aus Rüstungsindustrie Heidelberger Druckmaschinen-Aktie +35 Prozent: Erster Auftrag aus Rüstungsindustrie
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Ãœbersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Acurx Pharmaceuticals Aktie

Handeln
Aktien-Sparplan anlegen
0,3315 EUR -0,0135 EUR -3,91 %
BMN
0,3800 USD -0,0170 USD -4,28 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.10,86 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3CSCG

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00510M1045

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolACXP

Acurx Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference
PR NewswireAcurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection
PR NewswireAcurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
PR NewswireAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
PR NewswireAcurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
PR NewswireAcurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update
PR NewswireAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
PR NewswireAcurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update
PR NewswireAcurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development
PR NewswireAcurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
PR NewswireAcurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024
PR NewswireAcurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
PR NewswireAcurx to present at the 42nd Annual J.P. Morgan Healthcare Conference
PR NewswireAcurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure
PR NewswireAcurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
PR NewswireAcurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
PR NewswireAcurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update
PR NewswireAcurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences
PR NewswireAcurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection
PR NewswireAcurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress
PR NewswireAcurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023
PR NewswireAcurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update
PR NewswireAcurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business Update
PR NewswireAcurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023
PR NewswireAcurx Pharmaceuticals to Participate in the Maxim Group LLC Virtual Healthcare Conference on Tuesday, June 20, 2023 to Thursday, June 22, 2023 at 9 am ET
PR NewswireAcurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business Update
PR NewswireAcurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business Update
PR NewswireAcurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference
PR NewswireFDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference
PR NewswireAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
PR NewswireAcurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update
PR NewswireAcurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023
PR NewswireAcurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update
PR NewswireAcurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and Provide Business Update
PR NewswireAcurx Announces Scientific Oral and Poster Presented at IDWeek 2022
PR NewswireAcurx Announces Scientific Oral and Poster Presentations at IDWeek
PR NewswireAcurx Pharmaceuticals, Inc. Reports Second Quarter 2022 Results and Provides Business Update
PR NewswireAcurx Pharmaceuticals, Inc. to Discuss 2022 Second Quarter Financial Results on August 16, 2022 Conference Call and Provide Business Update
PR NewswireAcurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America

Acurx Pharmaceuticals News

Acurx Pharmaceuticals News: auf dieser Seite finden Sie alle Acurx Pharmaceuticals News und Nachrichten zur Acurx Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Acurx Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Acurx Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.